GlassScriptPhysician profile
Anand Madan
NPI 1366418006
$23,498.75
in general payments reported to CMS, 2019-2025
43 companies · $4,198 in 2025
The $4,198 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,998 · 2020: $2,562 · 2021: $2,456 · 2022: $3,327 · 2023: $3,399 · 2024: $4,560 · 2025: $4,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,874.72 |
| Education | $282.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,078.04 | 2019-2025 | |
| Janssen Biotech, INC. | $2,243.44 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,897.60 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,668.27 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $1,387.86 | 2019-2025 | Livdelzi |
| Genzyme Corporation | $1,287.44 | 2022-2025 | |
| Qol Medical, LLC | $1,010.85 | 2019-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $933.49 | 2020-2023 | |
| Pfizer INC. | $684.42 | 2019-2025 | |
| Madrigal Pharmaceuticals | $677.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $663.89 | 2019-2023 | Dificid |
| Celgene Corporation | $564.52 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $485.34 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $480.34 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $429.26 | 2024-2025 | Vowst, Zenpep |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $381.33 | 2023-2025 | Ibsrela |
| Romark Laboratories, Lc | $324.06 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $275.10 | 2019-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $252.04 | 2019-2024 | Rebyota |
| Braintree Laboratories, INC. | $216.98 | 2019-2022 | |
| Daiichi Sankyo INC. | $172.48 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $165.31 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $118.73 | 2022 | |
| Alexion Pharmaceuticals, INC. | $113.67 | 2019 | |
| Organon LLC | $106.03 | 2022-2024 | |
| Redhill Biopharma INC. | $104.21 | 2020-2022 | |
| Shionogi INC | $102.79 | 2019-2020 | |
| Boston Scientific Corporation | $101.55 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $93.72 | 2019-2023 | Linzess |
| Celltrion USA INC. | $81.61 | 2024-2025 | Vegzelma |
| Exact Sciences Corporation | $72.36 | 2023 | Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $67.79 | 2023-2024 | Idacio |
| Novo Nordisk INC | $39.54 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $38.02 | 2025 | Tremfya |
| Biocon Biologics INC | $36.04 | 2025 | Yesintek |
| Ucb, INC. | $24.01 | 2019 | |
| Sandoz INC. | $21.84 | 2023 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $21.11 | 2024 | Terlivaz |
| Alfasigma USA, INC. | $17.05 | 2020 | |
| Alnylam Pharmaceuticals INC. | $15.33 | 2021 | |
| Capsovision, INC. | $15.32 | 2025 | Capsocam Plus |
| Olympus America INC. | $15.07 | 2024 | Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Ethicon US, LLC | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Madan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.